All
Opdivo Granted FDA Approval for Some Colorectal Cancers
August 1st 2017Opdivo (nivolumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of both adult and pediatric patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) who have progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan.
Making Progress for Myelodysplastic Syndrome
July 25th 2017In an interview with CURE, Rami Komrokji, M.D., a hematologist at Moffitt Cancer Center in Tampa, Florida, discusses the advances that have been made in MDS in the past few years, as well as the MDS Clinical Research Consortium and its importance.
FDA Approves Yervoy for Pediatric Melanoma Population
July 24th 2017Yervoy (ipilimumab) was granted approval by the Food and Drug Administration (FDA) for the treatment of pediatric patients who are 12 years old or younger and have unresectable or metastatic melanoma, according to Bristol-Myers Squibb (BMS), the manufacturer of the CTLA-4 inhibitor.
Sexual Intimacy After Breast Cancer, a Taboo Subject
July 24th 2017Sexual intimacy is a subject that is difficult for many breast cancer survivors to discuss. The challenges of sexual intimacy are often created as a direct result of cancer treatments or can occur from the after effects which result in emotional scarring.